Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

G1 Therapeutics (GTHX) Stock Forecast & Price Target

G1 Therapeutics logo
Get the Latest News and Ratings for GTHX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors.

Sign Up

GTHX Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
5 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$4.00$4.00$4.00$11.80
Forecasted Upside-44.06% Downside-44.06% Downside-43.82% Downside610.84% Upside
Consensus Rating
Hold
Hold
Reduce
Moderate Buy

GTHX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GTHX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

G1 Therapeutics Stock vs. The Competition

TypeG1 TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-44.06% Downside27,482.23% Upside9.87% Upside
News Sentiment Rating
Neutral News

See Recent GTHX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/8/2024HC Wainwright
2 of 5 stars
E. White
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2024Wedbush
4 of 5 stars
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2024Needham & Company LLC
2 of 5 stars
G. Blum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
10/6/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
2/13/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$35.00 ➝ $19.00+468.86%
1/4/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:14 AM ET.


GTHX Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for G1 Therapeutics is $4.00, with a high forecast of $6.00 and a low forecast of $3.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GTHX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GTHX, but not buy additional shares or sell existing shares.

According to analysts, G1 Therapeutics's stock has a predicted downside of -44.06% based on their 12-month stock forecasts.

Analysts like G1 Therapeutics less than other "medical" companies. The consensus rating for G1 Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GTHX compares to other companies.


This page (NASDAQ:GTHX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners